WAM
VIVO

Wakefield Asset Management’s Meridian Bioscience Inc VIVO Stock Holding History

Wakefield Asset Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-35,058
Closed -$920K – 171
2021
Q1 		$920K Buy
+35,058
New +$834K 0.37% 68

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wakefield Asset Management's VIVO Position: Q2 2021 in Review

Wakefield Asset Management sold out of Meridian Bioscience Inc (VIVO) in Q2 2021, closing a stake of 35,058 shares — an estimated $920K sold.

Wakefield Asset Management first reported a position in VIVO in Q1 2021 and held it in 1 quarter. The position peaked at $920K in Q1 2021. 189 funds tracked by Wall St. Rank hold VIVO as of Q2 2021.

  • Wakefield Asset Management reported no remaining Meridian Bioscience Inc position as of Q2 2021 after selling out during the quarter.
  • Wakefield Asset Management sold 35,058 Meridian Bioscience Inc shares in Q2 2021, an estimated $920K.
  • Wakefield Asset Management first reported a position in Meridian Bioscience Inc in Q1 2021 and held it in 1 quarter.
  • Wakefield Asset Management's Meridian Bioscience Inc position peaked at $920K in Q1 2021.
  • 189 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2021.

Based on Wakefield Asset Management's 13F filing for Q2 2021, filed 10 Aug 2021.